Fallopian tube carcinosarcoma
diseaseOn this page
Also known as fallopian tube malignant mixed mesodermal (mullerian) tumorfallopian tube malignant mixed mesodermal (mullerian) tumourfallopian tube malignant mixed mesodermal (Müllerian) tumorfallopian tube malignant mixed mesodermal (Müllerian) tumourfallopian tube malignant mixed Mullerian tumour
Summary
Fallopian tube carcinosarcoma (MONDO:0006207) is a disease and 12 clinical trials. Top therapeutic interventions include bevacizumab, diphtheria toxoid, and pegcetacoplan. A subtype of carcinosarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 12
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | fallopian tube carcinosarcoma |
| Mondo ID | MONDO:0006207 |
| EFO | EFO:1000252 |
| DOID | DOID:1970 |
| NCIT | C40124 |
| UMLS | C1517117 |
| MedGen | 273294 |
| GARD | 0024330 |
| Anatomy (UBERON) | UBERON:0003889 |
| Is cancer (heuristic) | no |
Also known as: fallopian tube carcinosarcoma · fallopian tube malignant mixed mesodermal (mullerian) tumor · fallopian tube malignant mixed mesodermal (mullerian) tumour · fallopian tube malignant mixed mesodermal (Müllerian) tumor · fallopian tube malignant mixed mesodermal (Müllerian) tumour · fallopian tube malignant mixed Mullerian tumour
Disease family
This is a subtype of carcinosarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant mixed neoplasm › carcinosarcoma › fallopian tube carcinosarcoma
Related subtypes (2): ovarian carcinosarcoma, uterine carcinosarcoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 12.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 5 |
| PHASE2 | 3 |
| PHASE1/PHASE2 | 3 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04919629 | PHASE2 | RECRUITING | APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion |
| NCT05920798 | PHASE1/PHASE2 | RECRUITING | Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
| NCT06639074 | PHASE2 | RECRUITING | Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial |
| NCT02364713 | PHASE2 | TERMINATED | MV-NIS or Investigator’s Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer |
| NCT05494580 | PHASE1/PHASE2 | COMPLETED | Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer |
| NCT06393751 | PHASE1/PHASE2 | WITHDRAWN | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer |
| NCT04092270 | PHASE1 | ACTIVE_NOT_RECRUITING | A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer |
| NCT06483048 | PHASE1 | RECRUITING | MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer |
| NCT00989651 | PHASE1 | COMPLETED | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT02020707 | PHASE1 | COMPLETED | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers |
| NCT03924245 | PHASE1 | TERMINATED | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers |
| NCT03641287 | Not specified | TERMINATED | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BEVACIZUMAB | 4 | 5 |
| DIPHTHERIA TOXOID | 4 | 1 |
| PEGCETACOPLAN | 4 | 1 |
| TETANUS TOXOID | 4 | 1 |
| TOPOTECAN HYDROCHLORIDE | 4 | 1 |
| VELIPARIB | 3 | 2 |
| ENTINOSTAT | 3 | 1 |
| PAMIPARIB | 3 | 1 |
| SURUFATINIB | 3 | 1 |
| ASTX-660 | 1 | 1 |
| NEDISERTIB | 1 | 1 |
| CHEMBL3919533 | 0 | 1 |